Literature DB >> 32384264

Peripheral circulation miRNA expression of pediatric brain tumors and its relation to tumor miRNA expression levels.

Markus Bookland1,2, Eileen Gillan3, Xianyuan Song4, Antonina Kolmakova2.   

Abstract

OBJECTIVE: Micro RNAs (miRNAs) in peripheral biofluids (e.g., blood, saliva, urine) have been investigated as potential sources of diagnostic and prognostic information for a variety of tumor types, including pediatric brain tumors. While significant predictive associations have been identified between unique serum miRNA concentrations and some pediatric brain tumors, it is unclear whether serum miRNA abnormalities in pediatric brain tumor patients are representative of miRNA alterations in the tumor tissue compartment or whether they represent host tissue reactions to the presence of a brain tumor. The authors sought to identify whether serum miRNA changes in pediatric brain tumor patient sera could be explained by miRNA alterations within their tumors.
METHODS: Matched serum and tissue samples were taken from a cohort of pediatric brain tumor patients (juvenile pilocytic astrocytoma [JPA] = 3, medulloblastoma = 4, ependymoma = 3), and unmatched control samples (n = 5) were acquired from control pediatric patients without oncological diagnoses. Extracted RNAs were tested within an array of 84 miRNAs previously noted to be relevant in a variety of brain tumors.
RESULTS: miR-26a-5p correlated strongly in JPA patients within both the serum and tumor tissue samples (R2 = 0.951, p = 0.046), and serum levels were highly predictive of JPA (area under the curve = 0.751, p = 0.027). No other miRNAs that were significantly correlated between biological compartments were significantly associated with brain tumor type. In total, 15 of 84 tested miRNAs in JPA patients, 14 of 84 tested miRNAs in ependymoma patients, and 4 of 84 tested miRNAs in medulloblastoma patients were significantly, positively correlated between serum and tumor tissue compartments (R2 > 0.950, p < 0.05).
CONCLUSIONS: The majority of miRNA changes in pediatric brain tumor patient sera that are significantly associated with the presence of a brain tumor do not correlate with brain tumor miRNA expression levels. This suggests that peripheral miRNA changes within pediatric brain tumor patients likely derive from tissues other than the tumors themselves.

Entities:  

Keywords:  biomarker; ependymoma; juvenile pilocytic astrocytoma; medulloblastoma; miRNA; oncology; serum; tissue

Year:  2020        PMID: 32384264     DOI: 10.3171/2020.2.PEDS19715

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  4 in total

Review 1.  Liquid Biomarkers for Pediatric Brain Tumors: Biological Features, Advantages and Perspectives.

Authors:  Sibylle Madlener; Johannes Gojo
Journal:  J Pers Med       Date:  2020-11-27

Review 2.  An Overview of Intracranial Ependymomas in Adults.

Authors:  Giuseppe Lombardi; Alessandro Della Puppa; Marco Pizzi; Giulia Cerretti; Camilla Bonaudo; Marina Paola Gardiman; Angelo Dipasquale; Fabiana Gregucci; Alice Esposito; Debora De Bartolo; Vittorina Zagonel; Matteo Simonelli; Alba Fiorentino; Francois Ducray
Journal:  Cancers (Basel)       Date:  2021-12-05       Impact factor: 6.639

3.  MicroRNA-125a-3p, -4530, and -92a as a Potential Circulating MicroRNA Panel for Noninvasive Pancreatic Cancer Diagnosis.

Authors:  Ali Seyed Salehi; Negar Parsa-Nikoo; Farnaz Roshan-Farzad; Roshanak Shams; Mohadeseh Fathi; Hamid Asaszadeh Aghdaei; Ali Behmanesh
Journal:  Dis Markers       Date:  2022-10-08       Impact factor: 3.464

4.  A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors.

Authors:  Maria Sromek; Grzegorz Rymkiewicz; Agnieszka Paziewska; Lukasz Michal Szafron; Maria Kulecka; Michalina Zajdel; Mariusz Kulinczak; Michalina Dabrowska; Aneta Balabas; Zbigniew Bystydzienski; Magdalena Chechlinska; Jan Konrad Siwicki
Journal:  Biomolecules       Date:  2021-09-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.